… The protein is expressed in basal cells in normal human epithelium, but no data are … in
carcinoma. We studied bcl-2 expression in patients with non-small-cell lung carcinoma and …

… Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC) remain
unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a median …

… On the basis of evidence of activity in two patients with non–small-cell lung cancer with
ALK … who had non–small-cell lung cancer with prospectively identified ALK rearrangement. …

… lung cancer. Targeted therapy has emerged as an important mean of the disease management
for patients with non-small-cell lung cancer … clinical trials in lung cancer. Chemotherapy is …

… The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma (NSCLC)
as consisting of patients with a T1 or T2 primary tumor designation and no evidence of …

… ), is the most frequently mutated oncogene in human cancer, with mutations occurring in
approximately 25% of non–small-cell lung cancers (NSCLCs). Mutations in KRAS G12C occur …

… Lung cancer is the leading cause of cancer-related death worldwide with a high annual …
Non-small cell lung cancer (NSCLC) is the most common type of lung cancers, representing ~90…

… for advanced non-small-cell lung cancer has … on cancer growth. In this comprehensive
review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer…

… Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

… Systemically, the arsenal of agents used to treat metastatic non-small-cell lung cancer (NSCLC)
has also expanded dramatically with the targeting of mutant oncogenes by tyrosine-…